Critical role of nitric oxide in the modulation of prepulse inhibition in Swiss mice

Psychopharmacology

Volumn 231, Issue 4, 2014, Pages 663-672

  Issy, Ana C ^a   Pedrazzi, João Francisco C ^a   Yoneyama, Bruno H ^a   Del Bel, Elaine A ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Amphetamine; Nitric oxide; Phosphodiesterases; Prepulse inhibition; Schizophrenia

Indexed keywords

ACOUSTIC STIMULATION; AMPHETAMINE; ANIMALS; CYCLIC AMP; CYCLIC GMP; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANYLATE CYCLASE; INHIBITION (PSYCHOLOGY); MALE; MICE; NEUROPSYCHOLOGICAL TESTS; NITRIC OXIDE; NITRIC OXIDE DONORS; NITROPRUSSIDE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PURINONES; SENSORY GATING; STARTLE REACTION;

EID: 84893957793     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3277-4     Document Type: Article

References (85)

1. Akhondzadeh S, Ghayyoumi R, Rezaei F, Salehi B, Modabbernia AH, Maroufi A, Esfandiari GR, Naderi M, Ghebleh F, Tabrizi M, Rezazadeh SA (2011) Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial. Psychopharmacology (Berl) 213:809-815
2. Amann LC, Gandal MJ, Halene TB, Ehrlichman RS, White SL, McCarren HS, Siegel SJ (2010) Mouse behavioral endophenotypes for schizophrenia. Brain Res Bull 83:147-161
3. Baba H, Suzuki T, Arai H, Emson PC (2004) Expression of nNOS and soluble guanylate cyclase in schizophrenic brain. Neuroreport 15:677-680
4. Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488-520
5. Bernstein HG, Bogerts B, Keilhoff G (2005) The many faces of nitric oxide in schizophrenia. A review. Schizophr Res 78:69-86
6. Bernstein HG, Keilhoff G, Steiner J, Dobrowolny H, Bogerts B (2011) Nitric oxide and schizophrenia: present knowledge and emerging concepts of therapy. CNS Neurol Disord Drug Targets 10:792-807
7. Bird DC, Bujas-Bobanovic M, Robertson HA, Dursun SM (2001) Lack of phencyclidine-induced effects in mice with reduced neuronal nitric oxide synthase. Psychopharmacology (Berl) 155:299-309
8. Braff DL, Geyer MA (1990) Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry 47:181-188
9. Braff DL, Geyer MA, Light GA, Sprock J, Perry W, Cadenhead KS, Swerdlow NR (2001a) Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophr Res 49:171-178
10. Braff DL, Geyer MA, Swerdlow NR (2001b) Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156:234-258
11. Broersen LM, Feldon J, Weiner I (1999) Dissociative effects of apomorphine infusions into the medial prefrontal cortex of rats on latent inhibition, prepulse inhibition and amphetamine-induced locomotion. Neuroscience 94:39-46
12. Bujas-Bobanovic M, Bird DC, Robertson HA, Dursun SM (2000) Blockade of phencyclidine-induced effects by a nitric oxide donor. Br J Pharmacol 130:1005-1012
13. Carlsson A (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1:179-186
14. Coskran TM, Morton D, Menniti FS, Adamowicz WO, Kleiman RJ, Ryan AM, Strick CA, Schmidt CJ, Stephenson DT (2006) Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem 54:1205-1213
15. Coyle JT (2006) Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 26:365-384
16. Crofton KM (1990) Reflex modification and the detection of toxicant-induced auditory dysfunction. Neurotoxicol Teratol. 12:461-468
17. de Lima TC, Davis M (1995) Involvement of cyclic AMP at the level of the nucleus reticularis pontis caudalis in the acoustic startle response. Brain Res 700:59-69
18. Depoortere R, Perrault G, Sanger DJ (1997) Potentiation of prepulse inhibition of the startle reflex in rats: pharmacological evaluation of the procedure as a model for detecting antipsychotic activity. Psychopharmacology (Berl) 132:366-374
19. Derbyshire ER, Marletta MA (2012) Structure and regulation of soluble guanylate cyclase. Annu Rev Biochem 81:533-559
20. Deutsch SI, Rosse RB, Schwartz BL, Fay-McCarthy M, Rosenberg PB, Fearing K (1997) Methylene blue adjuvant therapy of schizophrenia. Clin Neuropharmacol. 20:357-363
21. Domek-Łopacińska K, Strosznajder JB (2008) The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging. Brain Res 1216:68-77
22. Ellenbroek BA, Budde S, Cools AR (1996) Prepulse inhibition and latent inhibition: the role of dopamine in the medial prefrontal cortex. Neuroscience 75:535-542
23. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156:117-154
24. Geyer MA, McIlwain KL, Paylor R (2002) Mouse genetic models for prepulse inhibition: an early review. Mol Psychiatry 7:1039-1053
25. Goff DC, Cather C, Freudenreich O, Henderson DC, Evins AE, Culhane MA, et al. (2009) A placebo-controlled study of sildenafil effects on cognition in schizophrenia. Psychopharmacology (Berl) 202: 411-17
26. Gould TJ, Bizily SP, Tokarczyk J, Kelly MP, Siegel SJ, Kanes SJ, Abel T (2004) Sensorimotor gating deficits in transgenic mice expressing a constitutively active form of Gs alpha. Neuropsychopharmacology 29:494-501
27. Gourgiotis I, Kampouri NG, Koulouri V, Lempesis IG, Prasinou MD, Georgiadou G, Pitsikas N (2012) Nitric oxide modulates apomorphine-induced recognition memory deficits in rats. Pharmacol Biochem Behav 102:507-514
28. Graham FK (1975) The more or less startling effects of weak pre-stimulation. Psychophysiology 12:238-248
29. Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R, Langen B, Logue S, Brennan J, Jiang L, Charych E, Egerland U, Liu F, Marquis KL, Malamas M, Hage T, Comery TA, Brandon NJ (2009) Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther 331:574-590
30. Graybiel AM (2000) The basal ganglia. Curr Biol 10:R509-R511
31. Halene TB, Siegel SJ (2008) Antipsychotic-like properties of phosphodiesterase 4 inhibitors: evaluation of 4-(3-butoxy-4-methoxybenzyl)-2- imidazolidinone (RO-20-1724) with auditory event-related potentials and prepulse inhibition of startle. J Pharmacol Exp Ther 326:230-239
32. Hallak JE, Maia-de-Oliveira JP, Abrao J, Evora PR, Zuardi AW, Crippa JA, Belmonte-de-Abreu P, Baker GB, Dursun SM (2013) Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial. JAMA Psychiatry 70:668-676
33. Hartung H, Threlfell S, Cragg SJ (2011) Nitric oxide donors enhance the frequency dependence of dopamine release in nucleus accumbens. Neuropsychopharmacology 36: 1811-22
34. Harvey BH, Nel A (2003) Role of aging and striatal nitric oxide synthase activity in an animal model of tardive dyskinesia. Brain Res Bull 61:407-416
35. Hosseini-Sharifabad A, Ghahremani MH, Sabzevari O, Naghdi N, Abdollahi M, Beyer C, Bollen E, Prickaerts J, Roghani A, Sharifzadeh M (2012) Effects of protein kinase A and G inhibitors on hippocampal cholinergic markers expressions in rolipram- and sildenafil-induced spatial memory improvement. Pharmacol Biochem Behav 101:311-319
36. Howes OD, Kapur S (2009) The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophr Bull 35:549-562
37. Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, Kapur S (2012) The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 69:776-786
38. Issy AC, Salum C, Del Bel EA (2009) Nitric oxide modulation of methylphenidate-induced disruption of prepulse inhibition in Swiss mice. Behav Brain Res 205:475-481
39. Issy AC, Lazzarini M, Szawka RE, Carolino RO, Anselmo-Franci JA, Del Bel EA (2011) Nitric oxide synthase inhibitors improve prepulse inhibition responses of Wistar rats. Behav Brain Res 217:416-423
40. Johansson C, Jackson DM, Svensson L (1997) Nitric oxide synthase inhibition blocks phencyclidine-induced behavioural effects on prepulse inhibition and locomotor activity in the rat. Psychopharmacology (Berl) 131:167-173
41. Kanes SJ, Tokarczyk J, Siegel SJ, Bilker W, Abel T, Kelly MP (2007) Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neuroscience 144:239-246
42. Kapur S, Mamo D (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27:1081-1090
43. Kapur S, Seeman P (2001) Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 158:360-369
44. Karatinos J, Rosse RB, Deutsch SI (1995) The nitric oxide pathway:potential implications for treatment of neuropsychiatric disorders. Clin Neuropharmacol 18:482-499
45. Kehne JH, Boulis NM, Davis M (1991) Effects of the phosphodiesterase inhibitor rolipram on the acoustic startle response in rats. Psychopharmacology (Berl) 105:27-36
46. Kelly MP, Stein JM, Vecsey CG, Favilla C, Yang X, Bizily SF, Esposito MF, Wand G, Kanes SJ, Abel T (2009) Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Galphas, a G-protein subunit genetically linked to schizophrenia. Mol Psychiatry 14(398-415):347
47. Kiss JP, Zsilla G, Vizi ES (2004) Inhibitory effect of nitric oxide on dopamine transporters: interneuronal communication without receptors. Neurochem Int 45:485-489
48. Klamer D, Engel JA, Svensson L (2001) The nitric oxide synthase inhibitor, L-NAME, block phencyclidine-induced disruption of prepulse inhibition in mice. Psychopharmacology (Berl) 156:182-186
49. Klamer D, Engel JA, Svensson L (2004) The neuronal selective nitric oxide synthase inhibitor, Nomega-propyl-L-arginine, blocks the effects of phencyclidine on prepulse inhibition and locomotor activity in mice. Eur J Pharmacol 503:103-107
50. Klamer D, Pålsson E, Fejgin K, Zhang J, Engel JA, Svensson L (2005) Activation of a nitric-oxide-sensitive cAMP pathway with phencyclidine: elevated hippocampal cAMP levels are temporally associated with deficits in prepulse inhibition. Psychopharmacology (Berl) 179:479-488
51. Kleppisch T, Feil R (2009) cGMP signalling in the mammalian brain: role in synaptic plasticity and behaviour. Handb Exp Pharmacol 549-579
52. Koch M (1999) The neurobiology of startle. Prog Neurobiol 59:107-128
53. Koch M, Bubser M (1994) Deficient sensorimotor gating after 6-hydroxydopamine lesion of the rat medial prefrontal cortex is reversed by haloperidol. Eur J Neurosci 6:1837-1845
54. Laruelle M, Kegeles LS, Abi-Dargham A (2003) Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann N Y Acad Sci 1003:138-158
55. Lau YS, Petroske E, Meredith GE, Wang JQ (2003) Elevated neuronal nitric oxide synthase expression in chronic haloperidol-treated rats. Neuropharmacology 45:986-994
56. Lin CH, Lane HY, Tsai GE (2012) Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacol Biochem Behav 100:665-677
57. Maxwell CR, Kanes SJ, Abel T, Siegel SJ (2004) Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications. Neuroscience 129:101-107
58. Negrete-Díaz JV, Baltazar-Gaytán E, Bringas ME, Vazquez-Roque RA, Newton S, Aguilar-Alonso P, León-Chávez BA, Flores G (2010) Neonatal ventral hippocampus lesion induces increase in nitric oxide [NO] levels which is attenuated by subchronic haloperidol treatment. Synapse 64:941-947
59. Padovan-Neto FE, Echeverry MB, Chiavegatto S, Del-Bel E (2011) Nitric oxide synthase inhibitor improves de novo and long-term l-DOPA-induced dyskinesia in hemiparkinsonian rats. Front Syst Neurosci 5:40
60. Pereira M, Siba IP, Chioca LR, Correia D, Vital MA, Pizzolatti MG, Santos AR, Andreatini R (2011) Myricitrin, a nitric oxide and protein kinase C inhibitor, exerts antipsychotic-like effects in animal models. Prog Neuropsychopharmacol Biol Psychiatry 35:1636-1644
61. Picconi B, Bagetta V, Ghiglieri V, Paillè V, Di Filippo M, Pendolino V, Tozzi A, Giampà C, Fusco FR, Sgobio C, Calabresi P (2011) Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. Brain 134:375-387
62. Pycock CJ, Kerwin RW, Carter CJ (1980) Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature 286:74-76
63. Ramirez J, Garnica R, Boll MC, Montes S, Rios C (2004) Low concentration of nitrite and nitrate in the cerebrospinal fluid from schizophrenic patients: a pilot study. Schizophr Res 68:357-361
64. Reif A, Herterich S, Strobel A, Ehlis AC, Saur D, Jacob CP, Wienker T, Töpner T, Fritzen S, Walter U, Schmitt A, Fallgatter AJ, Lesch KP (2006) A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function. Mol Psychiatry 11:286-300
65. Rutten K, Van Donkelaar EL, Ferrington L, Blokland A, Bollen E, Steinbusch HW, Kelly PA, Prickaerts JH (2009) Phosphodiesterase inhibitors enhance object memory independent of cerebral blood flow and glucose utilization in rats. Neuropsychopharmacology 34:1914-1925
66. Salum C, Guimarães FS, Brandão ML, Del Bel EA (2006) Dopamine and nitric oxide interaction on the modulation of prepulse inhibition of the acoustic startle response in the Wistar rat. Psychopharmacology (Berl) 185:133-141
67. Salum C, Raisman-Vozari R, Michel PP, Gomes MZ, Mitkovski M, Ferrario JE, Ginestet L, Del Bel EA (2008) Modulation of dopamine uptake by nitric oxide in cultured mesencephalic neurons. Brain Res 1198:27-33
68. Salum C, Issy AC, Brandão ML, Guimarães FS, Bel EA (2011) Nitric oxide modulates dopaminergic regulation of prepulse inhibition in the basolateral amygdala. J Psychopharmacol 25:1639-1648
69. Scatton B, Worms P, Lloyd KG, Bartholini G (1982) Cortical modulation of striatal function. Brain Res 232:331-343
70. Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, Proulx-LaFrance C, Majchrzak MJ, Ramirez AD, Schmidt K, Seymour PA, Siuciak JA, Tingley FD, Williams RD, Verhoest PR, Menniti FS (2008) Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 325:681-690
71. Siuciak JA (2008) The role of phosphodiesterases in schizophrenia: therapeutic implications. CNS Drugs 22:983-993
72. Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, Shrikhande A, Wong S, Menniti FS, Schmidt CJ (2006) Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 51:386-396
73. Soderling SH, Bayuga SJ, Beavo JA (1999) Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci U S A 96:7071-7076
74. Strick CA, James LC, Fox CB, Seeger TF, Menniti FS, Schmidt CJ (2010) Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A. Neuropharmacology 58:444-451
75. Swerdlow NR, Benbow CH, Zisook S, Geyer MA, Braff DL (1993) A preliminary assessment of sensorimotor gating in patients with obsessive compulsive disorder. Biol Psychiatry 33: 298-301
76. Swerdlow NR, Paulsen J, Braff DL, Butters N, Geyer MA, Swenson MR (1995) Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's Disease. J Neurol Neurosur Psychiatry 58:192-200
77. Swerdlow NR, Braff DL, Geyer MA (2000) Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. Behav Pharmacol 11:185-204
78. Swerdlow NR, Geyer MA, Braff DL (2001) Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl) 156:194-215
79. Taneli F, Pirildar S, Akdeniz F, Uyanik BS, Ari Z (2004) Serum nitric oxide metabolite levels and the effect of antipsychotic therapy in schizophrenia. Arch Med Res 35:401-405
80. Trabace L, Kendrick KM, Castrignanò S, Colaianna M, De Giorgi A, Schiavone S, Lanni C, Cuomo V, Govoni S (2007) Soluble amyloid beta1-42 reduces dopamine levels in rat prefrontal cortex: relationship to nitric oxide. Neuroscience 147:652-663
81. Weber M, Breier M, Ko D, Thangaraj N, Marzan DE, Swerdlow NR (2009) Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine. Psychopharmacology (Berl) 203:723-735
82. West AR, Galloway MP, Grace AA (2002) Regulation of striatal dopamine neurotransmission by nitric oxide: effector pathways and signaling mechanisms. Synapse 44:227-245
83. Wiley JL, Golden KM, Bowen SE (1997) Effects of modulation of nitric oxide on acoustic startle responding and prepulse inhibition in rats. Eur J Pharmacol 328:125-130
84. Wratten NS, Memoli H, Huang Y, Dulencin AM, Matteson PG, Cornacchia MA, Azaro MA, Messenger J, Hayter JE, Bassett AS, Buyske S, Millonig JH, Vieland VJ, Brzustowicz LM (2009) Identification of a schizophrenia-associated functional noncoding variant in NOS1AP. Am J Psychiatry 166:434-441
85. Xie Z, Adamowicz WO, Eldred WD, Jakowski AB, Kleiman RJ, Morton DG, Stephenson DT, Strick CA, Williams RD, Menniti FS (2006) Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience 139:597-607